Provided by Tiger Fintech (Singapore) Pte. Ltd.

SpringWorks Therapeutics, Inc.

46.96
+0.18000.38%
Post-market: 47.010.0500+0.11%18:15 EDT
Volume:11.12M
Turnover:522.32M
Market Cap:3.54B
PE:-13.76
High:47.02
Open:46.99
Low:46.95
Close:46.78
Loading ...

SpringWorks Therapeutics up 13% following Reuters report of takeover talks

TIPRANKS
·
10 Feb

SpringWorks Therapeutics Shares Halted; Report Says Merck KGaA in Talks to in Talks to Buy Co

THOMSON REUTERS
·
10 Feb

SpringWorks Therapeutics trading halted, volatility trading pause

TIPRANKS
·
10 Feb

Exclusive-Merck KGaA in Advanced Discussions to Acquire SpringWorks Therapeutics , Sources Say

THOMSON REUTERS
·
10 Feb

Analysts Expect Breakeven For SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Before Long

Simply Wall St.
·
05 Feb

SpringWorks should be bought on weakness, says JPMorgan

TIPRANKS
·
14 Jan

TD sees ‘some disappointment’ with lack of SpringWorks Therapeutics M&A news

TIPRANKS
·
14 Jan

Springworks Therapeutics Reports Preliminary Q4, Full-Year 2024 Net Product Revenue

MT Newswires Live
·
13 Jan

BRIEF-Rappta Therapeutics Enters Into A Global License Agreement With Springworks Therapeutics

Reuters
·
13 Jan

SpringWorks Therapeutics Reported Q4 OGSIVEO Revenue Of $61.5M, Cash Balance Of $461.9M

Benzinga
·
13 Jan

Rappta Therapeutics : Financials Include a $13 Mln Upfront Payment and Potential Milestones Payments

THOMSON REUTERS
·
13 Jan

Rappta Therapeutics Enters Into a Global License Agreement With SpringWorks Therapeutics for a Pre-Clinical First-in-Class Molecular Glue Targeting Pp2a

THOMSON REUTERS
·
13 Jan

SpringWorks Therapeutics Inc - to Seek EU Approval for Ogsiveo, Launch in Germany Mid-2025

THOMSON REUTERS
·
13 Jan

SpringWorks Therapeutics: Expects Cash Position to Fund Operations Through Profitability, Which Co Anticipates Achieving in First Half 2026

THOMSON REUTERS
·
13 Jan

SpringWorks Therapeutics : Preliminary Q4 and 2024 U.S. Net Product Revenue for Ogsiveo Were $61.5 Mln and $172.0 Mln

THOMSON REUTERS
·
13 Jan

Market Today: Quantum Stocks Tumble Despite IonQ's Optimistic Forecast

GuruFocus
·
11 Jan

SpringWorks Therapeutics rumor highlighted in Betaville alert

TIPRANKS
·
11 Jan

SpringWorks Therapeutics price target lowered to $78 from $80 at Guggenheim

TipRanks
·
09 Jan

SpringWorks Therapeutics Is Maintained at Buy by Guggenheim

Dow Jones
·
09 Jan

SpringWorks Therapeutics price target lowered to $55 from $58 at BofA

TipRanks
·
08 Jan